Anavex Life Sciences Corp (AVXL)

[Gator328]

SAVA's diagnostic blood test has the potential to make billions of dollars. There are probably competitors but the point is that if Anavex could get into the diagnostic and preventative markets simultaneously it would be excellent horizontal integration.

It would also take a competing drug off the market. At this point it's a foot race to the FDA and AVXL gave up some of its lead to focus on Rett, PDD, etc.

An acquisition like this would strengthen AVXL's moat. But for now it's too expensive with AVXL's market cap undervalued relative to its peers.